NCT04791553View on ClinicalTrials.gov

Safety Study of Cenobamate in Subjects With Normal Hepatic Function and Subjects With Severe Hepatic Impairment

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

June 17, 2021

Primary Completion Date

November 15, 2022

Study Completion Date

August 11, 2023

Conditions
Hepatic Impairment
Interventions
DRUG

Cenobamate

Cenobamate (YKP3089) is a small molecule approved in the United States (US) for the treatment of partial onset seizures (POS) in adult patients.

Trial Locations (2)

83101

Summit Clinical Research s.r.o., Bratislava

51-162

Centrum Badan Klinicznych Piotr Napora lekarze sp.p.,, Wroclaw

All Listed Sponsors
lead

SK Life Science, Inc.

INDUSTRY